Shifts in Funding Priorities and Vaccine Guidance Contribute to Safety Myths, Plus Reactions to Ruling in U.S. v. Skrmetti — The Monitor

This volume examines how the cancellation of contracts to develop a bird flu vaccine and unfounded claims by new vaccine advisors reflect persistent myths about the safety of mRNA technology. It also explores false claims linking COVID-19 vaccines to miscarriage and analyzes how reactions to a Supreme Court ruling on gender-affirming care for minors highlights…

Read More

Impact of financial incentives on the value of the marginal drug

From an interesting review paper in the Journal of Economic Perspectives by Craig Garthwaite: Although research and development investments clearly respond to market opportunities, the exact benefits created by these incremental investments remain unclear. This is largely because the exact marginal products developed in response to these incentives are elusive to identify. Certainly, the amount…

Read More

Novavax Sees Sanofi Vaccine Pact as Model for Future Deals, Some Going Beyond Infectious Disease

Novavax’s partnership with Sanofi allows the pharma giant to explore potential combinations of assets from both companies, and it’s a blueprint for the kinds of alliances the vaccine developer is pursuing. Rather than commercializing vaccines, Novavax aims to turn its research into business development deals, R&D executive Ruxandra Draghia-Akli said. The post Novavax Sees Sanofi…

Read More